
|Articles|March 1, 1997
Supplements and Featured Publications
- Integrating Risk Factor Management of Coronary Heart Disease into Managed Care
- Volume 3
- Issue 3 Suppl
Safety and Tolerability of Lipid-Lowering Drugs After Heart Transplantation: The Heart Transplant Lipid Registry
Author(s)Christie M. Ballantyne, MD
Advertisement
Articles in this issue
almost 29 years ago
Goals and Objectivesalmost 29 years ago
Introductionalmost 29 years ago
Integrating Risk Factor Management into the Care of the Cardiac Patientalmost 29 years ago
Risk-Factor Management in Women and Other Special Patientsalmost 29 years ago
Risk Factor Management: Exploring the Boundariesalmost 29 years ago
CME Quizalmost 29 years ago
BibliographyNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Fixed-Duration Epcoritamab Plus Chemotherapy Yields Response, Remissions in DLBCL
2
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
3
EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma
4
In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison
5














































